1. At a Glance
Anlon Healthcare, a Rajkot-based API and pharma intermediate maker, is coming to Dalal Street with a ₹121 Cr IPO (fresh issue only). Price band is ₹86–₹91, with lot size of 164 shares (min retail ticket ~₹14K). Promoters Punitkumar Rasadia, Meet Vachhani, and Mamata Rasadia are diluting their ownership from ~70% pre-issue to ~52% post. Listing is slated for 3rd September 2025 on NSE & BSE.
Translation: A chemical company that finally wants to test its chemistry with investors.
2. Introduction
Incorporated in 2013, Anlon makes high-purity pharma intermediates and APIs, the backbone of every “take one tablet twice daily” prescription. With 65 commercialized products, 28 at pilot stage, and 49 in lab testing, this looks like a chemistry lab on steroids.
They boast 21 Drug Master Files filed globally and approvals from ANVISA, NMPA, PMDA. Basically, they’ve got passports stamped in multiple jurisdictions. But here’s the twist — FY24 revenue fell sharply before doubling again in FY25. Investors love “V-shaped recoveries,” but in pharma, that’s usually code for “regulatory hiccups + delayed approvals.”
3. Business Model (WTF Do They Even Do?)
- Pharma Intermediates – Cyanoethylbenzoic acid, Ketonitrile, etc. Think of them as raw dough before it becomes the bread (API).
- APIs – Loxoprofen, Ketoprofen, Dexketoprofen… the painkillers you’ve popped at least once. These are the molecules that actually go into your medicines, nutraceuticals, personal care and even veterinary products.
- Custom Manufacturing – Contract manufacturing of complex chemicals for global clients. This is where margins get interesting because custom = premium.
Strength: Long approval cycles = high entry barriers.
